We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction, and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
qordata Releases Open Payments Data 2016
Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
Regulator visitors to this blog will know how important it is for qordata to get facts about pharmaceutical spend data right. We would go so far as to say that protecting the sanctity, validity and relevance of this data has a sacred status with us. But before data can be all this, it needs to undergo a number of internal and external processes. Unlike many of the technically-sophisticated and complex processes needed for onward submission, one of the most basic, and most critical requires neither. That process is: Giving data the right context. In a webinar-cum-discussion I hosted last month, I asked my panelists about some of the challenges they face in their organizations’ compliance programs. All three panelists Elizabeth […]
In our last blog, we described spend differences in Grant payments and alluded to how drug launch and approval could have contributed to this. This blog takes a more in-depth take on how spend by drug has changed in 2016. Insight #4 Say Yes To Drugs (But Only Some Of Them) This year, when qordata’s data team listed the top ten drugs that drew the most spend, we observed that a full 50% belonged to oncology. That’s right. Spending on cancer treatment registered most spending from pharmaceutical companies across the United States. Questions arising from this are: How did YoY spend-by-drug patterns change within this category? In the five months that data was collected in 2013, the proportion of oncology […]
People seeking spend data on a specific physician will be searching through more than 600,000 physicians and/or going through 1,100 teaching hospital records with the latest update CMS makes in its Open Payments Database. At qordata, we have employed our data engineering chops to make your life just that much easier. This is the second of a three-part series describing seven instant insights from the CMS Open Payments Data Release 2016*. How have medical device and drug manufacturers’ spend patterns changed in each since the introduction of the Sunshine Payments Act? How many ways can a medical drug/device manufacturer make a transfer of value (ToV) to a physician or teaching hospital? Seventeen. You might be familiar with R&D, Consulting Fees […]